Cost-Effectiveness of Etoricoxib for Ankylosing Spondylitis in Norway
Author Information
Author(s): Jansen Jeroen P., Taylor Stephanie D.
Primary Institution: Mapi Values, Boston, MA, USA
Hypothesis
To evaluate the cost-effectiveness of etoricoxib compared to celecoxib and nonselective NSAIDs in treating ankylosing spondylitis.
Conclusion
Etoricoxib is the most cost-effective NSAID for initiating treatment of ankylosing spondylitis in Norway.
Supporting Evidence
- Etoricoxib is associated with about 0.4 more quality adjusted life years than other interventions over a 30-year time horizon.
- At 1 year, naproxen is the most cost-saving strategy, but etoricoxib becomes cost-effective after 5 years.
- There is a >95% probability that etoricoxib is the most cost-effective treatment when considering a time horizon of 5 or more years.
Takeaway
This study found that etoricoxib is a better choice than other pain medications for people with a specific type of back pain called ankylosing spondylitis because it saves money and helps patients live better.
Methodology
A Markov state-transition model was used to estimate costs and benefits associated with initiating treatment with different NSAIDs.
Potential Biases
Potential overestimation of cardiovascular risks due to assumptions made in the model.
Limitations
The analysis may not be applicable to other countries due to differences in treatment practices and costs.
Participant Demographics
The average age of the AS population in the model was assumed to be 45 years.
Statistical Information
P-Value
p<0.05
Confidence Interval
95% CrI
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website